Evidence map›Paper›PMID 40259683›Full record

ArticleFuture medicinal chemistry2025

Identification of novel

Galyna P Volynets, Olga I Gudzera, Segiy S Lukashov, Oksana B Gorbatiuk, Mariia O Usenko, Tetiana P Ruban, Mykola V Protopopov, Segiy S Tarnavskiy, Igor M Kotey, Volodymyr G Bdzhola and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Future medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Galyna P VolynetsDepartment of Medicinal Chemistry, Institute of Molecular Biology and Genetics, The NAS of Ukraine, Kyiv, Ukraine.ORCID 0000-0002-0166-2642
Olga I GudzeraDepartment of Protein Synthesis Enzymology, Institute of Molecular Biology and Genetics, The NAS of Ukraine, Kyiv, Ukraine.
Segiy S LukashovDepartment of Medicinal Chemistry, Institute of Molecular Biology and Genetics, The NAS of Ukraine, Kyiv, Ukraine.
Oksana B GorbatiukDepartment of Cell Regulatory Mechanisms, Institute of Molecular Biology and Genetics, The NAS of Ukraine, Kyiv, Ukraine.
Mariia O UsenkoDepartment of Cell Regulatory Mechanisms, Institute of Molecular Biology and Genetics, The NAS of Ukraine, Kyiv, Ukraine.
Tetiana P RubanDepartment of Human Genetics, Institute of Molecular Biology and Genetics, The NAS of Ukraine, Kyiv, Ukraine.
Mykola V ProtopopovResearch and Development Department, Chemspace LLC, Kyiv, Ukraine.
Segiy S TarnavskiyDepartment of Medicinal Chemistry, Institute of Molecular Biology and Genetics, The NAS of Ukraine, Kyiv, Ukraine.
Igor M KoteyDepartment of Medicinal Chemistry, Institute of Molecular Biology and Genetics, The NAS of Ukraine, Kyiv, Ukraine.
Volodymyr G BdzholaDepartment of Medicinal Chemistry, Institute of Molecular Biology and Genetics, The NAS of Ukraine, Kyiv, Ukraine.
Andrii O Prykhod'koDepartment of Medicinal Chemistry, Institute of Molecular Biology and Genetics, The NAS of Ukraine, Kyiv, Ukraine.
Lubov L LukashDepartment of Human Genetics, Institute of Molecular Biology and Genetics, The NAS of Ukraine, Kyiv, Ukraine.
Sergiy M YarmolukDepartment of Medicinal Chemistry, Institute of Molecular Biology and Genetics, The NAS of Ukraine, Kyiv, Ukraine.
Michael A TukaloDepartment of Protein Synthesis Enzymology, Institute of Molecular Biology and Genetics, The NAS of Ukraine, Kyiv, Ukraine.

Funding

PATHOGENIC MECHANISMS OF MYCOBACTERIUM TUBERCULOSISZ01AI000693 · NIAID · NIAID EXTRAMURAL ACTIVITIES · PI BARRY, CLIFTON · 1993 to 2008
$8.1M
Intramural NIH HHS Z01 AI000693
6 · The paper itself

Abstract

backgroundTuberculosis has become the world's most lethal infectious disease. A major challenge in treating tuberculosis is the multidrug resistance of MATERIALS AND

methodsThe virtual screening of compound collection containing about 250,000 ligands into aminoacyl-adenylate binding site of

resultsAccording to the data of biochemical screening, we have found

conclusion

Indexed as

Anti-Bacterial AgentsAntitubercular AgentsEnzyme InhibitorsLeucine-tRNA LigaseMycobacterium tuberculosisHumansMicrobial Sensitivity TestsMolecular Docking SimulationMolecular StructureStructure-Activity RelationshipAnti-Bacterial AgentsAntitubercular AgentsEnzyme InhibitorsLeucine-tRNA Ligaseaminoacylation assayinhibitorleucyl-tRNA synthetasemolecular dockingMycobacterium tuberculosisN-(5-Benzyl-thiazol-2-yl)-2-(1-phenyl-1H-tetrazol-5-ylsulfanyl)-acetamide

Identifiers

PMID40259683
PMCPMC12026236

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.